Cataba­sis shares are shred­ded af­ter lead drug flops in PhII Duchenne MD study

Cataba­sis’ lead drug just flopped in a Phase II study for Duchenne mus­cu­lar dy­s­tro­phy, evis­cer­at­ing its stock af­ter yet an­oth­er clin­i­cal set­back rais­es ques­tions about its com­pe­tence and di­rec­tion.

The drug, CAT-1004 (edasa­lonex­ent), failed to reg­is­ter a sig­nif­i­cant bio­mark­er ef­fect on mus­cle in­flam­ma­tion, look­ing very much like the place­bo.

The edasa­lonex­ent 100 mg/kg/day treat­ment group “con­sis­tent­ly showed nu­mer­i­cal im­prove­ment ver­sus place­bo across mul­ti­ple mea­sures,” Cataba­sis re­port­ed, but none of them were sta­tis­ti­cal­ly sig­nif­i­cant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER